Statin use and risk of endometrial cancer: a nationwide registry-based case–control study

Acta Obstetricia et Gynecologica Scandinavica

Volumn 96, Issue 2, 2017, Pages 144-149

  Sperling, Cecilie D ^a   Verdoodt, Freija ^a   Friis, Søren ^a,b,c   Dehlendorff, Christian ^a   Kjaer, Susanne K ^a,d  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d University of Copenhagen   (Denmark)

Author keywords

case control; endometrial neoplasms; pharmacoepidemiology; risk; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DENMARK; DIABETES MELLITUS; DISEASE DURATION; EDUCATIONAL STATUS; ENDOMETRIUM CANCER; FEMALE; HORMONE SUBSTITUTION; HUMAN; MIDDLE AGED; OBESITY; PARITY; PRESCRIPTION; PRIORITY JOURNAL; VERY ELDERLY; YOUNG ADULT; ENDOMETRIAL NEOPLASMS; REGISTER; RISK; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DENMARK; ENDOMETRIAL NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MIDDLE AGED; OBESITY; REGISTRIES; RISK;

EID: 85008455605     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.13069     Document Type: Article

References (26)

1. Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120(2 Pt 1):383–97.
2. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769–81.
3. Schointuch MN, Gilliam TP, Stine JE, Han X, Zhou C, Gehrig PA, et al. Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer. Gynecol Oncol. 2014;134:346–55.
4. Matusewicz L, Meissner J, Toporkiewicz M, Sikorski AF. The effect of statins on cancer cells – review. Tumour Biol. 2015;36:4889–904.
5. Altwairgi AK. Statins are potential anticancerous agents (review). Oncol Rep. 2015;33:1019–39.
6. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, et al. Incidence of cancer and statin usage – record linkage study. Int J Cancer. 2010;126:279–84.
7. Yu O, Boudreau DM, Buist DS, Miglioretti DL. Statin use and female reproductive organ cancer risk in a large population-based setting. Cancer Causes Control. 2009;20:609–16.
8. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008;17:27–36.
9. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology. 2007;18:213–9.
10. Liu Y, Qin A, Li T, Qin X, Li S. Effect of statin on risk of gynecologic cancers: a meta-analysis of observational studies and randomized controlled trials. Gynecol Oncol. 2014;133:647–55.
11. Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7 Suppl):22–5.
12. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39(7 Suppl):42–5.
13. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(7 Suppl):38–41.
14. WHO. Guidelines for ATC classification and DDD assignment: WHO Collaborating Centre for Drug Statistics Methodology. 2015. Available online at: http://www.whocc.no/atc_ddd_index/ (accessed September 27, 2016).
15. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–90.
16. Jensen VM, Rasmussen AW. Danish Education Registers. Scand J Public Health. 2011;39(7 Suppl):91–4.
17. Blenstrup LT, Knudsen LB. Danish registers on aspects of reproduction. Scand J Public Health. 2011;39(7 Suppl):79–82.
18. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915–20.
19. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2013.
20. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 2011;71:1763–71.
21. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31:2607–18.
22. Zhang Y, Liu H, Yang S, Zhang J, Qian L, Chen X. Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. Int J Biol Markers. 2014;29:e21–9.
23. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387:1094–108.
24. Riahi S, Fonager K, Toft E, Hvilsted-Rasmussen L, Bendsen J, Paaske Johnsen S, et al. Use of lipid-lowering drugs during 1991-98 in Northern Jutland, Denmark. Br J Clin Pharmacol. 2001;52:307–11.
25. Svensson E, Nielsen RB, Hasvold P, Aarskog P, Thomsen RW. Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish population-based study. Clin Epidemiol. 2015;7:213–23.
26. Barfoed BL, Paulsen MS, Christensen PM, Halvorsen PA, Kjaer T, Larsen ML, et al. Associations between patients’ risk attitude and their adherence to statin treatment – a population based questionnaire and register study. BMC Fam Pract. 2016;17:28.